VTR Stock Analysis: Ventas | NYSE
REIT - Healthcare Facilities | NYSE, USA | Market Cap: 46.794m USD | 12M Return: 57.4% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 310M
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 7
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Ventas, Inc. (NYSE: VTR) is a Chicago-based S&P 500 healthcare REIT founded in 1983 and publicly listed since 1998. The company owns and operates approximately 1,400 properties across North America and the United Kingdom, anchored by more than 850 senior housing communities and supplemented by outpatient medical buildings, research centers, and other healthcare facilities. Ventas combines an owned-property portfolio with senior housing operating platforms and uses its Ventas OI data platform to guide investment and operational decisions. As a healthcare REIT, Ventas primarily generates revenue through long-term triple-net leases, real estate ownership, and senior housing operations, and is required to distribute the majority of its taxable income to shareholders as dividends.
- Senior housing occupancy and rate growth expand NOI
- Interest rate hikes pressure cap rates and borrowing costs
- Aging population tailwinds drive sustained senior housing demand
| Net Income: 260.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -2.51 > 1.0 |
| NWC/Revenue: -18.82% < 20% (prev -13.69%; Δ -5.14% < -1%) |
| CFO/TA 0.06 > 3% & CFO 1.75b > Net Income 260.4m |
| Net Debt (12.8b) to EBITDA (2.45b): 5.20 < 3 |
| Current Ratio: 0.15 > 1.5 & < 3 |
| Outstanding Shares: last quarter (486.7m) vs 12m ago 9.03% < -2% |
| Gross Margin: -4.26% > 18% (prev 42.48%; Δ -46.74% > 0.5%) |
| Asset Turnover: 22.83% > 50% (prev 19.52%; Δ 3.31% > 0%) |
| Interest Coverage Ratio: 1.34 > 6 (EBIT TTM 1.02b / Interest Expense TTM 760.6m) |
| A: -0.04 (Total Current Assets 201.3m - Total Current Liabilities 1.36b) / Total Assets 27.7b |
| B: -0.28 (Retained Earnings -7.73b / Total Assets 27.7b) |
| C: 0.04 (EBIT TTM 1.02b / Avg Total Assets 26.9b) |
| D: 0.90 (Book Value of Equity 13.1b / Total Liabilities 14.5b) |
| Altman-Z'' = 0.02 = B |
| DSRI: 0.55 (Receivables 254.9m/382.0m, Revenue 6.13b/5.08b) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.09 (AQ_t 0.09 / AQ_t-1 0.95) |
| SGI: 1.21 (Revenue 6.13b / 5.08b) |
| TATA: -0.05 (NI 260.4m - CFO 1.75b) / TA 27.7b) |
| Beneish M = -3.79 (Cap -4..+1) = AAA |
As of July 28, 2026, the stock is trading at USD 100.11 with a total of 2,136,621 shares traded. Over the past week, the price has changed by +4.01%, over one month by +12.76%, over three months by +18.89% and over the past year by +57.40%.
Current recommended Stop Loss: 97.40 (which is 2.7% or 1.3 ATR below the current price).
Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.
- StrongBuy: 12
- Buy: 5
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 98.1 | -2% |
P/E Trailing = 178.0364
P/E Forward = 158.7302
P/S = 7.4901
P/B = 3.5997
P/EG = 1.7374
Revenue TTM = 6.13b USD
EBIT TTM = 1.02b USD
EBITDA TTM = 2.45b USD
Long Term Debt = 12.5b USD (from longTermDebt, last quarter)
Short Term Debt = 65.0m USD (from shortLongTermDebt, last quarter)
Debt = 12.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 207.7m
Net Debt = 12.8b USD (calculated: Debt 12.9b - CCE 183.6m)
Enterprise Value = 59.5b USD (46.8b + Debt 12.9b - CCE 183.6m)
Interest Coverage Ratio = 1.34 (Ebit TTM 1.02b / Interest Expense TTM 760.6m)
EV/FCF = 124.7x (Enterprise Value 59.5b / FCF TTM 477.4m)
FCF Yield = 0.80% (FCF TTM 477.4m / Enterprise Value 59.5b)
FCF Margin = 7.78% (FCF TTM 477.4m / Revenue TTM 6.13b)
Net Margin = 4.25% (Net Income TTM 260.4m / Revenue TTM 6.13b)
Gross Margin = -4.26% ((Revenue TTM 6.13b - Cost of Revenue TTM 6.39b) / Revenue TTM)
Gross Margin QoQ = 39.56% (prev -136.0%)
Tobins Q-Ratio = 2.15 (Enterprise Value 59.5b / Total Assets 27.7b)
Interest Expense / Debt = 5.88% (Interest Expense 760.6m / Debt 12.9b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 805.9m (EBIT 1.02b * (1 - 21.00%))
Current Ratio = 0.15 (Total Current Assets 201.3m / Total Current Liabilities 1.36b)
Debt / Equity = 0.99 (Debt 12.9b / totalStockholderEquity, last quarter 13.1b)
Debt / EBITDA = 5.20 (Net Debt 12.8b / EBITDA 2.45b)
Debt / FCF = 26.71 (Net Debt 12.8b / FCF TTM 477.4m)
Total Stockholder Equity = 12.4b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.97% (Net Income 260.4m / Total Assets 27.7b)
RoE = 2.10% (Net Income TTM 260.4m / Total Stockholder Equity 12.4b)
RoCE = 4.11% (EBIT 1.02b / Capital Employed (Equity 12.4b + L.T.Debt 12.5b))
RoIC = 3.08% (NOPAT 805.9m / Invested Capital 26.1b)
WACC = 5.03% (E(46.8b)/V(59.7b) * Re(5.14%) + D(12.9b)/V(59.7b) * Rd(5.88%) * (1-Tc(0.21)))
Discount Rate = 5.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.24 | Cagr: 8.28%
[DCF] Terminal Value 73.10% ; FCFF base≈727.1m ; Y1≈637.6m ; Y5≈515.2m
[DCF] Fair Price = N/A (negative equity: EV 8.27b - Net Debt 12.8b = -4.48b; debt exceeds intrinsic value)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.0 | # QB: 0
Revenue Correlation: 98.48 | Revenue CAGR: 13.35% | SUE: 4.0 | # QB: 7
EPS current Quarter (2026-06-30): EPS=0.11 | Chg30d=-33.33% | Revisions=-40% | Analysts=2
EPS next Quarter (2026-09-30): EPS=0.15 | Chg30d=-28.57% | Revisions=-40% | Analysts=2
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=+0.00% | Revisions=-25% | GrowthEPS=+18.6% | GrowthRev=+18.3%
EPS next Year (2027-12-31): EPS=0.85 | Chg30d=+0.00% | Revisions=-40% | GrowthEPS=+58.3% | GrowthRev=+13.1%
[Analyst] Revisions Ratio: -70% (up=0, down=7)